Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
- Revenue in GBP (TTM)37.44bn
- Net income in GBP4.91bn
- Incorporated1992
- Employees89.90k
- LocationAstraZeneca PLCCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| Fusion Pharmaceuticals Inc | 16.77% | 2.30bn |
| Amolyt Pharma SAS | 14.90% | 1.05bn |
| Gracell Biotechnologies Inc | 15.14% | 1.10bn |
| Icosavax Inc | 19.02% | 862.87m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi SA | 40.00bn | 3.56bn | 110.73bn | 87.99k | 30.74 | 1.78 | 20.13 | 2.77 | 3.36 | 3.36 | 37.84 | 58.10 | 0.3716 | 1.43 | 5.64 | 538,639.00 | 3.39 | 5.87 | 4.33 | 7.16 | 68.91 | 68.78 | 9.11 | 16.90 | 0.6484 | 34.81 | 0.2454 | 60.51 | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | 4.14 |
| Pfizer Inc | 42.40bn | -1.98bn | 126.39bn | 88.00k | -- | 1.89 | 40.12 | 2.98 | -0.4643 | -0.4646 | 9.81 | 15.48 | 0.255 | 1.47 | 5.15 | 632,295.40 | -1.17 | 8.20 | -1.43 | 10.40 | 71.29 | 69.34 | -4.61 | 22.68 | 0.602 | -- | 0.4412 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 23.57bn | 2.39bn | 136.12bn | 26.70k | 57.23 | 30.14 | 21.77 | 5.77 | 5.81 | 5.81 | 57.47 | 11.03 | 0.3415 | 1.75 | 4.85 | 1,158,577.00 | 3.46 | 10.36 | 4.39 | 13.06 | 63.30 | 75.41 | 10.12 | 26.51 | 0.8928 | 1.59 | 0.9136 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| AstraZeneca plc | 37.44bn | 4.91bn | 184.93bn | 89.90k | 37.95 | 6.14 | 20.99 | 4.94 | 3.14 | 3.14 | 23.97 | 19.42 | 0.4892 | 1.63 | 4.44 | 416,499.20 | 6.42 | 3.34 | 8.84 | 4.61 | 82.21 | 79.64 | 13.12 | 7.69 | 0.6905 | 7.91 | 0.4585 | 143.06 | 3.29 | 15.71 | 81.11 | 22.54 | 22.47 | 1.10 |
| Novartis AG | 37.22bn | 7.68bn | 192.43bn | 76.06k | 23.57 | 5.60 | 14.77 | 5.17 | 4.15 | 6.65 | 20.11 | 17.50 | 0.4687 | 1.77 | 5.61 | 545,344.30 | 9.67 | 8.53 | 13.56 | 11.23 | 74.75 | 72.93 | 20.64 | 22.68 | 0.7224 | 14.66 | 0.4085 | 67.20 | 7.57 | 0.2779 | 41.64 | -7.71 | 0.7808 | 6.19 |
| Roche Holding AG | 52.75bn | 9.53bn | 194.28bn | 103.61k | 20.08 | 7.31 | 14.57 | 3.68 | 13.23 | 13.23 | 73.21 | 36.32 | 0.6526 | 1.88 | 5.05 | 567,395.40 | 12.76 | 16.12 | 19.22 | 25.24 | 73.71 | 71.48 | 19.55 | 22.98 | 0.9656 | 17.08 | 0.5116 | 58.80 | -7.21 | 0.6494 | -7.43 | 1.90 | -1.13 | 1.99 |
| Merck & Co Inc | 47.61bn | 10.47bn | 223.78bn | 72.00k | 21.50 | 6.74 | 16.46 | 4.70 | 5.39 | 5.39 | 24.66 | 17.19 | 0.5756 | 2.44 | 5.51 | 867,763.90 | 12.67 | 7.70 | 16.42 | 10.29 | 75.79 | 72.26 | 22.01 | 15.03 | 1.22 | 23.69 | 0.464 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 41.91bn | 4.04bn | 261.39bn | 50.00k | 64.98 | 50.60 | 24.72 | 6.24 | 2.99 | 2.99 | 31.03 | 3.84 | 0.3967 | 4.43 | 4.74 | 1,100,000.00 | 3.86 | 6.55 | 5.27 | 8.40 | 66.65 | 69.74 | 9.73 | 16.46 | 0.7061 | 8.92 | 0.9119 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2023 | 68.51m | 4.42% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 65.12m | 4.20% |
| The Vanguard Group, Inc.as of 01 Sep 2024 | 57.22m | 3.69% |
| Norges Bank Investment Managementas of 01 Sep 2024 | 32.91m | 2.12% |
| BlackRock Fund Advisorsas of 01 Sep 2024 | 30.41m | 1.96% |
| Fidelity Management & Research Co. LLCas of 01 Sep 2024 | 15.76m | 1.02% |
| SSgA Funds Management, Inc.as of 01 Sep 2024 | 15.27m | 0.99% |
| Legal & General Investment Management Ltd.as of 01 Sep 2024 | 14.89m | 0.96% |
| BlackRock Advisors LLCas of 01 Sep 2024 | 14.02m | 0.90% |
| Invesco Asset Management Ltd.as of 01 Sep 2024 | 13.50m | 0.87% |
